How Gene Therapy Works

Gene therapy is a molecular medicine approach aimed at treating or preventing disease by modifying the genetic material within a patient’s cells. Rather than addressing symptoms alone, gene therapy targets the root cause of disease at the DNA level. The central concept involves introducing a functional copy of a gene into cells where the endogenous gene is absent, mutated, or improperly expressed.

There are several strategies employed in gene therapy. The most common is gene replacement therapy, where a normal copy of a defective gene is introduced to restore proper function. Another approach is gene addition, which provides cells with new genetic instructions that can compensate for disease processes. In some cases, gene silencing techniques (e.g., RNA interference) are used to suppress harmful gene expression. More advanced approaches include gene editing, where technologies such as CRISPR-based systems precisely correct mutations within the genome.

Gene therapy can be performed using two main delivery strategies: in vivo and ex vivo. In vivo therapy involves direct delivery of the therapeutic gene into the patient’s body, targeting specific tissues such as the liver, muscle, or lungs. In contrast, ex vivo therapy involves removing cells from the patient, genetically modifying them in a controlled laboratory environment, and then reintroducing the corrected cells back into the patient. This method is commonly used in hematopoietic stem cell therapies.

A critical distinction in gene therapy is between somatic and germline interventions. Somatic gene therapy targets non-reproductive cells and affects only the treated individual, making it ethically acceptable and widely practiced. Germline gene therapy, which modifies reproductive cells or embryos, results in heritable genetic changes and raises significant ethical, legal, and societal concerns.

The ultimate objective of gene therapy is to achieve sustained therapeutic benefit with minimal adverse effects. This requires efficient delivery, stable gene expression, and proper regulation of the introduced gene. Although challenges remain, gene therapy has shown remarkable success in treating certain inherited disorders, cancers, and viral infections, marking a paradigm shift in modern medicine.

Gene therapy has evolved from a simple “gene replacement” concept into a sophisticated field of precision genomic medicine. Today, it encompasses multiple strategies aimed at correcting, silencing, or rewriting genetic information to treat disease at its root cause.

At its core, gene therapy still begins with identifying a disease-associated genetic defect. However, modern approaches go beyond inserting a healthy copy of a gene. Scientists now tailor interventions depending on the pathology whether the goal is to restore function, reduce harmful gene expression, or precisely edit a mutation within the genome.

One major advancement is the refinement of delivery systems. While viral vectors (such as adeno-associated viruses, AAVs) remain widely used due to their high efficiency, newer non-viral platforms particularly lipid nanoparticles have gained prominence. These systems improve safety profiles, allow repeat dosing, and enable delivery of more complex payloads, including RNA and gene-editing machinery.

Gene therapy is a biomedical strategy designed to treat or prevent disease by directly modifying a patient’s genetic material. Instead of using conventional drugs to manage symptoms, gene therapy targets the underlying cause of disease at the DNA level. This approach is particularly relevant for inherited disorders, certain cancers, and some viral infections.

The process begins with identifying the faulty gene responsible for a disease (Figure 1). Many genetic disorders arise from mutations that either produce a nonfunctional protein or no protein at all. Once this defective gene is characterized, scientists design a therapeutic gene a correct, functional version intended to restore normal cellular function.

The next critical step is delivery. Because DNA cannot easily enter cells on its own, gene therapy relies on vectors vehicles engineered to transport genetic material into target cells. The most commonly used vectors are modified viruses, such as adenoviruses or lentiviruses, which have been altered to remove their disease-causing ability while retaining their efficiency in entering cells. Non-viral methods, including lipid nanoparticles and physical techniques, are also being developed to improve safety and specificity.

After administration, the vector carries the therapeutic gene into the patient’s cells. Depending on the approach, the new gene may integrate into the host genome or remain as an independent piece of DNA within the cell. Once inside, the cell’s machinery begins to express the introduced gene, producing the functional protein that was previously missing or defective. This restores, partially or fully, the normal biological process.

There are different modes of gene therapy. In in vivo therapy, the vector is delivered directly into the patient’s body, targeting specific tissues. In ex vivo therapy, cells are first removed from the patient, genetically modified in the laboratory, and then reintroduced. The latter allows for greater control and verification before treatment.

More advanced forms include gene editing technologies like CRISPR, which enable precise correction of mutations within the genome itself rather than simply adding a new gene.

Despite its promise, gene therapy faces challenges such as immune responses to vectors, limited duration of gene expression, and potential off-target effects. However, continuous advances in vector design, targeting strategies, and genome editing are steadily improving its safety and efficacy, making gene therapy a transformative frontier in modern medicine.

CRISPR (Clustered Regularly Interspaced Short Palindromic Repeats)

CRISPR (Clustered Regularly Interspaced Short Palindromic Repeats) is a natural defense mechanism found in many bacteria and archaea that protects them from invading genetic material, such as viruses. Scientists have adapted this system into a powerful gene-editing technology that can modify DNA with high precision. CRISPR is a gene-editing tool that uses a guide RNA and a CRISPR-associated enzyme, such as Cas9, to precisely target, edit and/or modify specific DNA sequences.

The best-known CRISPR system uses a guide RNA (gRNA) to identify a specific DNA sequence and an enzyme, commonly Cas9, to cut the DNA at or near that target. Once the DNA is cut, the cell’s natural repair mechanisms can be used to disable a gene, correct a mutation, or introduce a desired genetic change. Other CRISPR-associated enzymes, such as Cas12 and Cas13, can target DNA or RNA and have expanded the technology’s applications.

CRISPR has transformed biological research because it is relatively fast, adaptable, and cost-effective compared with many earlier gene-editing methods. It is used in agriculture to develop crops with improved disease resistance, nutritional characteristics, or tolerance to environmental stresses. In livestock research, CRISPR is being investigated for improving animal health and productivity and reducing susceptibility to certain diseases.

CRISPR also has applications in medicine, biotechnology, and pathogen detection. However, challenges remain, including unintended genetic changes (off-target effects), delivery into cells, ethical considerations, regulatory issues, and potential ecological consequences.

CRISPR is closely related to gene therapy because it can be used to correct, remove, or replace disease-causing genetic mutations in a patient’s cells. In CRISPR-based gene therapy, the editing system is delivered to target cells, where it makes a precise change to the genome. This approach has potential for treating inherited disorders, cancers, and other diseases caused by genetic abnormalities. Unlike conventional gene therapy, which often adds a functional copy of a gene, CRISPR can directly modify the patient’s existing DNA.

Genetic basis of disease

Genes are the fundamental units of heredity and are composed of deoxyribonucleic acid (DNA), a double-helical molecule that encodes biological information in the form of nucleotide sequences. These sequences are organized into codons, each specifying particular amino acids that are assembled into proteins during gene expression. Proteins, in turn, perform most structural, enzymatic, and regulatory functions within the cell. Thus, genes indirectly control virtually all cellular processes, including metabolism, growth, differentiation, and response to environmental stimuli.

The flow of genetic information follows the central dogma of molecular biology: DNA is transcribed into messenger RNA (mRNA), which is then translated into proteins. Any disruption in this tightly regulated process can have significant consequences. Genetic mutations defined as changes in the nucleotide sequence can arise from replication errors, environmental factors (e.g., radiation, chemicals), or inherited defects. These mutations may be classified as point mutations, insertions, deletions, or chromosomal rearrangements.

Mutations can affect gene function in several ways. A missense mutation results in the substitution of one amino acid for another, potentially altering protein function. A nonsense mutation introduces a premature stop codon, leading to truncated, nonfunctional proteins. Frameshift mutations, caused by insertions or deletions, disrupt the reading frame entirely, often yielding severely defective proteins. Additionally, mutations in regulatory regions can alter gene expression levels rather than protein structure.

Genetic disorders arise when such mutations impair the normal function of critical proteins. For example, defective enzymes may disrupt metabolic pathways, while abnormal structural proteins may compromise tissue integrity. These disorders can be monogenic (caused by mutations in a single gene), such as cystic fibrosis or sickle cell disease, or polygenic/multifactorial, involving multiple genes and environmental influences.

Not all mutations are harmful; some are neutral or even beneficial. However, pathogenic mutations can lead to a loss of function, gain of function, or dominant-negative effects, each contributing differently to disease pathogenesis. Understanding the molecular basis of these defects is essential for designing targeted therapeutic interventions such as gene therapy.

Role of vectors in gene delivery

A major challenge in gene therapy is the efficient and targeted delivery of therapeutic DNA into host cells. Naked DNA molecules are generally unstable in biological environments and cannot easily cross cellular membranes due to their size and negative charge. To overcome these barriers, specialized delivery systems known as vectors are employed.

Vectors serve as carriers that transport genetic material into cells while protecting it from degradation. In molecular biology, vectors are typically engineered DNA molecules capable of replication and expression within host cells. They are designed to include essential elements such as promoters, enhancers, and selectable markers to ensure proper gene expression.

Vectors used in gene therapy are broadly classified into viral and non-viral systems.

Viral vectors used in gene therapy

Viruses have naturally evolved to deliver their genetic material into host cells efficiently, making them ideal candidates for gene delivery. In gene therapy, viruses are genetically modified to remove pathogenic components and insert therapeutic genes. Common viral vectors include:

Adenoviruses: Adenoviral vectors are widely used in gene therapy because of their high transduction efficiency and ability to infect a broad range of cell types, including both dividing and non-dividing cells. After entering the host cell via receptor-mediated endocytosis, the viral DNA is transported to the nucleus, where it remains episomal (extrachromosomal) rather than integrating into the host genome. This episomal nature allows adenoviruses to drive very high levels of transgene expression, making them particularly useful in applications where strong but short-term expression is required, such as cancer gene therapy or vaccination strategies.

However, because the DNA does not integrate, it is gradually lost as cells divide, resulting in transient expression. A major limitation of adenoviral vectors is their relatively high immunogenicity. The host immune system can recognize viral proteins, leading to inflammation and clearance of transduced cells. This can reduce therapeutic efficacy and complicate repeated dosing. Modern “gutless” or helper-dependent adenoviral vectors have been engineered to reduce these immune responses and improve safety.

Adeno-associated viruses (AAVs): AAV vectors are among the most promising tools in gene therapy due to their favorable safety profile and low immunogenicity. They are derived from non-pathogenic viruses and have not been associated with human disease. AAVs can efficiently infect both dividing and non-dividing cells, with different serotypes exhibiting specific tissue tropism (e.g., liver, muscle, or neurons). Unlike retroviruses, AAV genomes typically remain in the nucleus as episomal DNA concatemers, which are relatively stable and can support long-term gene expression, especially in non-dividing or slowly dividing cells.

In rare cases, AAV can integrate into the host genome at specific sites, but this is not the primary mechanism of persistence. One limitation of AAV vectors is their small packaging capacity (approximately 4.7 kb), which restricts the size of the therapeutic gene that can be delivered. Additionally, pre-existing immunity to AAV in some patients may reduce transduction efficiency. Despite these constraints, AAVs are extensively used in clinical gene therapy due to their balance of efficiency, durability of expression, and safety, particularly for treating inherited disorders affecting the liver, retina, and central nervous system.

Retroviruses and lentiviruses: These viral vectors insert (integrate) their genetic material directly into the host cell’s genome. Because the inserted gene becomes part of the host DNA, it is replicated along with the cell’s genome during cell division, resulting in stable and long-term gene expression. A key difference is that lentiviruses (a subtype of retroviruses) can infect both dividing and non-dividing cells, whereas most other retroviruses primarily infect dividing cells. This makes lentiviral vectors more versatile and widely useful in gene therapy applications.

Non-viral vectors used in gene therapy

Non-viral vectors are delivery systems used in gene therapy to introduce therapeutic genetic material into target cells without relying on modified viruses. They include chemical carriers, nanoparticles, and physical techniques. Compared with viral vectors, non-viral approaches generally have lower immunogenicity and reduced concerns about viral replication or insertional effects. However, their major limitation is often lower transfection efficiency and shorter-lasting gene expression. Non-viral systems are therefore an important area of gene-therapy research, particularly for applications requiring repeated administration, large genetic payloads, or improved safety profiles.

1. Liposomes and lipid nanoparticles

Liposomes and lipid nanoparticles (LNPs) are lipid-based delivery systems that can encapsulate and transport genetic material, including DNA, RNA, or other nucleic acids, into cells. Their lipid components interact with the cell membrane and facilitate cellular uptake, often through endocytosis. Once inside the cell, the genetic material can be released and, depending on the therapeutic strategy, reach the cytoplasm or nucleus. LNPs are particularly important in modern nucleic-acid delivery because their composition can be engineered to improve stability, targeting, and intracellular release. Their relatively low immunogenicity compared with many viral systems also makes them attractive for repeated therapeutic administration.

2. Polymeric nanoparticles

Polymeric nanoparticles use biodegradable or biocompatible polymers to package and protect therapeutic genetic material during delivery. The polymers can shield DNA or RNA from degradation by nucleases and help transport the genetic material across biological barriers. Their physical and chemical properties can be modified to control particle size, stability, cellular uptake, and release of the therapeutic cargo. Some polymeric systems are designed to release genetic material in response to specific intracellular conditions, such as changes in pH. Although they offer considerable flexibility and safety advantages, achieving efficient delivery to specific tissues and sufficient intracellular release remains a significant challenge.

3. Physical methods

Physical gene-delivery methods introduce genetic material directly into cells using mechanical or electrical forces. Electroporation temporarily creates pores in cell membranes using electrical pulses, allowing DNA or RNA to enter. Microinjection uses a fine needle to deliver genetic material directly into individual cells and is particularly useful in experimental research. Gene guns use microscopic particles coated with DNA and physically propel them into cells or tissues. These approaches can achieve effective delivery without viral carriers, but they may cause cellular damage, require specialized equipment, or be difficult to apply systematically throughout the body. Consequently, their use is often limited to specific experimental or localized applications.

Gene-therapy vectors versus epidemiological vectors

The term “vector” has different meanings in molecular biology and epidemiology. In gene therapy, a vector is a biological, chemical, or physical delivery system designed to transport therapeutic genetic material into target cells. Viral vectors, nanoparticles, and other delivery technologies are therefore considered gene-delivery vectors. In epidemiology and parasitology, however, a vector is typically a living organism that transmits an infectious agent between hosts. Examples include mosquitoes transmitting malaria parasites or ticks transmitting certain bacteria. Although the terminology is shared, these concepts are fundamentally different: gene-therapy vectors deliver therapeutic molecules, whereas epidemiological vectors transmit pathogens.

The distinction is particularly important because the two uses of the term “vector” describe completely different mechanisms. Gene-therapy vectors are deliberately designed or modified to achieve controlled delivery of genetic material, with characteristics such as tissue targeting, cellular uptake, and duration of gene expression being important considerations. In contrast, epidemiological vectors acquire and transmit infectious organisms as part of a biological transmission cycle. For example, a mosquito can transmit a parasite from one infected host to another susceptible host. Gene-therapy vectors do not normally reproduce or transmit disease in this epidemiological sense.

The major differences between viral and non-vectors used for gene therapy applications are as shown in Table 1.    

Table 1. Difference between viral and non-viral vectors

Viral vectors	Non-viral vectors
Highly efficient in transferring desired genes.	Less or fairly efficient in transferring desired genes.
Viral vectors pose some health risk to the recipient Patient.	Non-viral vectors are usually safer to use, and they do not pose any health risk to the recipient patient.
Viral vectors are used for in vivo gene therapy to deliver desired genes through the process of transduction.	Non-viral vectors are used for ex vivo gene therapy to deliver desired genes through the process known as transfection.
Viruses (e.g. adeno-associated viruses and adenoviruses) are used as vectors.	Non-viral vectors such as gene gun or microinjection and calcium phosphate precipitate are used as vehicles to convey the gene of interest into the body of the host.

Requirements for effective vectors used in gene therapy

For gene therapy to achieve consistent clinical success, the vectors used for gene delivery must satisfy a series of stringent biological and safety criteria. These requirements are essential because the vector not only transports the therapeutic gene but also determines how efficiently, specifically, and safely that gene is expressed within the patient. Poorly designed vectors can lead to low efficacy, unintended genetic effects, or harmful immune responses. Optimizing vector performance is central to the success of gene therapy applications. Vector design must prioritize biocompatibility, stability, and precision to ensure that therapeutic benefits outweigh potential risks. The following are important requirements or characteristics of vector used in gene therapy applications:

1. Targeting specific cell types: An effective vector must demonstrate cellular tropism, meaning it selectively targets the intended cell type or tissue. This specificity is critical because many genetic diseases affect particular cell populations, such as hepatocytes in liver disorders or neurons in neurodegenerative diseases. Targeting is achieved in viral vectors by engineering surface proteins (capsid or envelope proteins) that bind to specific receptors on target cells. In non-viral systems, ligands such as antibodies, peptides, or carbohydrates can be attached to delivery particles to guide them to specific tissues. Precise targeting reduces off-target effects, where unintended cells are transduced, which could lead to toxicity or unwanted gene expression. It also improves therapeutic efficiency by ensuring that a higher proportion of the delivered genetic material reaches the relevant cells.

2. Efficient cellular entry: Vectors must overcome multiple biological barriers to successfully deliver genetic material into cells. These include the cell membrane, endosomal compartments, and, ultimately, the nuclear envelope. Viral vectors are naturally efficient at this process. They typically enter cells via receptor-mediated endocytosis or direct membrane fusion, followed by release of their genetic material into the cytoplasm. Non-viral vectors, such as lipid nanoparticles, rely on similar endocytic pathways but often face challenges such as endosomal escape, where the DNA must avoid degradation within intracellular vesicles. Efficient cellular entry is crucial because poor uptake or intracellular degradation significantly reduces the amount of therapeutic gene that reaches the nucleus, thereby limiting gene expression and therapeutic benefit.

3. Genomic integration or persistence: Once inside the cell, the therapeutic gene must either integrate into the host genome or persist in a stable form. The choice between these two outcomes depends on the therapeutic objective. Genomic integration, as seen with retroviral and lentiviral vectors, enables long-term and potentially permanent gene expression because the inserted gene is replicated during cell division. This is particularly important for treating diseases in rapidly dividing tissues, such as blood cells. However, integration carries the risk of insertional mutagenesis, where the inserted DNA disrupts essential host genes or activates oncogenes, potentially leading to cancer. Alternatively, some vectors (e.g., adenoviral and AAV vectors) maintain the therapeutic gene as episomal DNA, which exists independently of the host genome. This approach reduces the risk of mutagenesis but may result in transient expression, especially in dividing cells where episomal DNA can be diluted over time.

4. Safety and low immunogenicity: A critical requirement for any gene therapy vector is that it must be safe and minimally immunogenic. The host immune system is highly sensitive to foreign genetic material and viral components. If a vector triggers a strong immune response, it can lead to inflammation, destruction of transduced cells, and reduced therapeutic efficacy. In severe cases, immune reactions may cause systemic toxicity. To address this, modern vectors are engineered to remove or modify immunogenic viral genes and reduce recognition by the immune system. Additionally, delivery strategies and dosing regimens are optimized to minimize immune activation. Low immunogenicity is especially important for therapies requiring repeated administration, as pre-existing or induced immunity can neutralize the vector before it reaches target cells.

5. Controlled gene expression: Successful gene therapy requires not just delivery of the gene, but also precise regulation of its expression. The therapeutic gene must be expressed at appropriate levels too little expression may be ineffective, while excessive expression can be toxic. To achieve this control, vectors are designed with specific promoters and regulatory elements that dictate when, where, and how strongly the gene is expressed. Tissue-specific promoters can restrict expression to particular cell types, while inducible systems allow gene expression to be turned on or off in response to external signals. Proper regulation ensures that the therapeutic protein is produced in a physiologically relevant manner, closely mimicking natural gene function.

6. Minimal toxicity and side effects: Vectors must exhibit minimal toxicity and should not disrupt normal cellular processes. This includes avoiding unintended interactions with host DNA, proteins, or signaling pathways. One major concern is the accidental activation of oncogenes or inactivation of tumor suppressor genes, which could promote uncontrolled cell growth. Additionally, excessive accumulation of vector components or expressed proteins may stress cellular systems and impair function.

Gene expression and therapeutic outcome

Following successful delivery of a therapeutic gene into a target cell, the ultimate effectiveness of gene therapy depends on how well that gene is expressed and translated into a functional biological outcome. Gene delivery alone is insufficient; the introduced genetic material must undergo a series of tightly coordinated intracellular processes to produce a functional protein capable of correcting the underlying defect. These processes collectively determine the therapeutic success or failure of the intervention, and they are as follows: 

1. Nuclear entry: A critical early step in gene expression is the delivery of the therapeutic DNA into the nucleus, which is the site of transcription in eukaryotic cells. This step presents a significant barrier, particularly in non-dividing cells, where the nuclear envelope remains intact and restricts access to large macromolecules such as DNA. Some viral vectors, such as lentiviruses and certain adeno-associated viruses, possess evolved mechanisms that actively transport their genetic material through nuclear pore complexes.

These mechanisms often involve nuclear localization signals that facilitate active import into the nucleus. In contrast, other vectors rely on cell division, during which the nuclear membrane temporarily disassembles, allowing DNA to passively enter the nuclear compartment. Inefficient nuclear entry can severely limit gene expression, as DNA that remains in the cytoplasm is more susceptible to degradation. Therefore, optimizing nuclear delivery is a key focus in vector engineering, especially for targeting terminally differentiated cells such as neurons or muscle cells.

2. Transcription and translation: Once inside the nucleus, the therapeutic gene must be properly transcribed into messenger RNA (mRNA) by the host cell’s transcriptional machinery. This requires the presence of functional regulatory elements within the vector, including promoters, enhancers, and polyadenylation signals. These elements ensure that transcription is initiated efficiently and that the resulting mRNA is stable and properly processed. After transcription, the mRNA is exported through nuclear pores into the cytoplasm, where it undergoes translation by ribosomes.

During this process, the nucleotide sequence of the mRNA is decoded into a specific sequence of amino acids, forming a polypeptide chain. Both transcription and translation must occur with high fidelity. Errors in transcription can produce unstable or nonfunctional mRNA, while errors in translation can lead to misfolded or truncated proteins. Additionally, the level of gene expression must be carefully balanced; insufficient expression may fail to achieve therapeutic benefit, whereas excessive expression may result in cellular stress or toxicity.

3. Protein function and cellular restoration: The newly synthesized protein must undergo proper folding to achieve its functional three-dimensional structure. This process is often assisted by molecular chaperones within the cell. In many cases, proteins also require post-translational modifications, such as phosphorylation, glycosylation, or cleavage, to become fully active. Equally important is the correct subcellular localization of the protein.

For instance, enzymes involved in metabolic pathways must localize to specific organelles such as mitochondria or lysosomes, while membrane proteins must be transported to the cell surface. Mislocalization can render an otherwise functional protein ineffective. Once properly processed and localized, the therapeutic protein can restore normal cellular function. For example, a missing enzyme can reestablish a disrupted metabolic pathway, while a functional structural protein can repair cellular architecture. This step represents the direct mechanistic link between gene delivery and phenotypic correction.

4. Therapeutic impact: The ultimate objective of gene therapy is to achieve a meaningful and sustained therapeutic outcome. This involves not only restoring normal cellular processes but also improving tissue and organ function at the physiological level. Depending on the condition being treated, the therapeutic effect may manifest as the correction of a biochemical imbalance, prevention of disease progression, or complete reversal of symptoms. In some cases, even partial restoration of protein function can significantly improve clinical outcomes.

Long-term or permanent therapeutic effects are more likely when gene expression is stable and maintained over time, particularly in non-dividing cells or when genomic integration occurs. However, challenges such as immune responses, gene silencing, or loss of expression can limit durability. The success of gene therapy depends on the precise coordination of all these steps from nuclear entry to protein function highlighting the complexity of translating genetic intervention into clinical benefit.

References

Sayed, N., Allawadhi, P., Khurana, A., Singh, V., Navik, U., Pasumarthi, S. K., Khurana, I., Banothu, A. K., Weiskirchen, R., & Bharani, K. K. (2022). Gene therapy: Comprehensive overview and therapeutic applications. Life Sciences, 294, 120375. 

Rashid, R. A., & Ankathil, R. (2020). Gene therapy: An updated overview on the promising success stories. Malaysian Journal of Pathology, 42(2), 171–185.

Alberts B, Bray D, Johnson A, Lewis J, Raff M, Roberts K and Walter P (1998). Essential Cell Biology: An Introduction to the Molecular Biology of the Cell. Third edition. Garland Publishing Inc., New York.

Dale J (2003). Molecular genetics of bacteria. Jeremy W. Dale and Simon Park (4^th eds.). John Wiley & Sons Ltd, West Sussex, UK.

Edelstein, M. L., Abedi, M. R., Wixon, J., and Edelstein, R. M. (2004). Gene therapy clinical trials worldwide 1989-2004—an overview. J Gene Med, 6: 597-602.

Ferrua, F.; Brigida, I.; Aiuti, A. (2010). Update on gene therapy for adenosine deaminase-deficient severe combined immunodeficiency. Current Opinion in Allergy and Clinical Immunology. 10 (6): 551–556.

Gardlík R, Pálffy R, Hodosy J, Lukács J, Turna J, Celec P; Pálffy; Hodosy; Lukács; Turna; Celec (2005). Vectors and delivery systems in gene therapy. Med Sci Monit. 11 (4): RA110–21.

Horn PA, Morris JC, Neff T, Kiem HP; Morris; Neff; Kiem (2004). Stem cell gene transfer—efficacy and safety in large animal studies. Mol. Ther. 10 (3): 417–31.

S Li and L Huang (2000). Nonviral gene therapy: promises and challenges. Gene Therapy, 7:31-34. www.nature.com/gt

Salmons B, Günzburg WH; Günzburg (1993). Targeting of retroviral vectors for gene therapy. Hum Gene Ther. 4 (2): 129–41.

Sambrook, J., Russell, D.W. (2001). Molecular Cloning: a Laboratory Manual, 3rd edn. Cold Spring Harbor Laboratory Press, New York.

Sheridan C (2011). Gene therapy finds its niche. Nature Biotechnology. 29 (2): 121–128.

Tamarin Robert H (2002). Principles of Genetics. Seventh edition. Tata McGraw-Hill Publishing Co Ltd, Delhi.     

Twyman R.M (1998). Advanced Molecular Biology: A Concise Reference. Bios Scientific Publishers. Oxford, UK.

Vannucci, L; Lai, M; Chiuppesi, F; Ceccherini-Nelli, L; Pistello, M (2013). Viral vectors: A look back and ahead on gene transfer technology. The new microbiologica. 36 (1): 1–22.